Composite films demonstrate sustained antibacterial activity against Staphylococcus aureus, highlighting their potential in packaging applications.
Biodegradable poly(lactic acid) (PLA)/poly(ε-caprolactone) (PCL) composite films were prepared with a compatibilizer (tributyl citrate, TBC) using a solvent casting method. Incorporation of 5% TBC (w/v, of PCL weight) improved tensile strength and elongation at break (21.93 ± 2.33 MPa and 21.02 ± 1.54%, respectively) and reduced water vapor permeability (from 0.12 ± 0.01 to 0.098 ± 0.01 g·mm·m2·h·kPa), indicating improved compatibility between PLA and PCL. Staphylococcus aureus phage PBSA08 demonstrated rapid and persistent bacteriolytic activity for up to 24 h, suggesting its potential as a promising antibacterial biological agent. To impart antibacterial properties to the developed PLA/PCL/TBC film, PBSA08 was loaded into sodium alginate (SA) and coated on the film surface. The optimal composition was 3% (w/v) SA and 3% (w/v) glycerol, which exhibited suitable dynamic behavior as a coating solution and excellent adhesion to the film surface. The phage-coated antibacterial films demonstrated progressive and significant inhibition against S. aureus starting from 10 to 24 h, with controlled phage-release properties. Overall, the developed active film might exert sustained and remarkable antibacterial effects through controlled release of biological agents (phage) under realistic packaging conditions.
No takes yet. Share an insight, caveat, or question.
Imm et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: